---
layout: post
title: "Notice of Approval of Product Under Voucher: Material Threat Medical Countermeasure Priority Review Voucher; FABHALTA"
date: 2026-02-05 18:53:10 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2024-00688
original_published: 2024-01-16 00:00:00 +0000
significance: 8.00
---

# Notice of Approval of Product Under Voucher: Material Threat Medical Countermeasure Priority Review Voucher; FABHALTA

**Published:** February 05, 2026 18:53 UTC
**Source:** Federal Register
**Original Published:** January 16, 2024 00:00 UTC
**Document Number:** 2024-00688

## Summary

The Food and Drug Administration (FDA) is announcing the approval of a product redeeming a material threat medical countermeasure (MCM) priority review voucher. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved material threat MCM product applications that meet certain criteria. FDA is required to publish notice of the issuance of material threat MCM priority review vouchers as well as the approval of products redeeming a voucher. FDA has determined that FABHALTA (iptacopan) capsules, approved December 5, 2023, meets the redemption criteria.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2024/01/16/2024-00688/notice-of-approval-of-product-under-voucher-material-threat-medical-countermeasure-priority-review)
- API: https://www.federalregister.gov/api/v1/documents/2024-00688

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
